Test Price
2,800 AED✅ Home Collection Available
JAK2 V617F Mutation Analysis (Somatic) by Next-Generation Sequencing (NGS) in Dubai, UAE
Executive Summary & Core Metrics
Clinical Excellence & Patient-First Logistics
- 99.9% Diagnostic Sensitivity – ISO 9001:2015‑accredited deep‑sequencing NGS, detecting variants down to 1% allele frequency.
- VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection – Available daily from 8 AM to 11 PM.
- Post‑Test Clinical Guidance – Telephonic interpretation with our specialist team after report delivery.
- Direct Insurance Billing – WhatsApp verification at +971 54 548 8731.
Test Overview & Methodology
This advanced genomic assay screens for the somatic JAK2 V617F mutation—a hallmark driver of polycythemia vera, essential thrombocythemia, and primary myelofibrosis—using next‑generation sequencing with unrivaled accuracy. Deep sequencing provides unparalleled sensitivity to detect low-level clones that conventional PCR often misses, enabling definitive diagnosis and minimal residual disease monitoring.
| Test Parameter | Our NGS Test | Standard PCR Test |
|---|---|---|
| Precision (Analytical Sensitivity) | 99.9% (deep sequencing, 1% VAF) | ~95% (often misses low‑level clones) |
| Methodology | Next‑Generation Sequencing (NGS) with bioinformatics curation | Allele‑specific PCR / Sanger sequencing |
| Turnaround Time | 14–21 business days (comprehensive report) | 1–2 weeks (limited loci) |
| Copy‑Number & Complex Variants | Detected | Not reliably reported |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403: “This NGS‑based JAK2 V617F test directly detects the clonal driver mutation essential for diagnosing polycythemia vera and related myeloproliferative neoplasms. Accurate interpretation requires integration of full blood counts, bone marrow morphology, and clinical presentation. An isolated mutation alone is not diagnostic. Patients must consult their hematologist for contextualized decision-making and should never discontinue prescribed therapies without professional guidance.”
Critical Medication Warning
Do not discontinue any prescribed medication, especially blood thinners, aspirin, or cytoreductive agents, without consulting your physician.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Minors cannot undergo genomic testing without written consent from a legal guardian per UAE Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Exclusion: Patients with uncontrolled bleeding disorders, active anticoagulation, or known allergy to antiseptic solutions must notify the phlebotomist prior to collection.
- Sample rejection: Heparin‑contaminated tubes are not accepted; only EDTA whole blood, extracted DNA, or FTA cards are valid.
- Red Flag: If you develop sudden severe headache, vision changes, chest pain, or limb swelling (possible thrombosis), go to the nearest emergency department immediately—do not wait for test results.
Patient FAQ & Clinical Guidance
1. What is the JAK2 V617F mutation test used for?
This test detects the somatic JAK2 V617F mutation, the hallmark driver of polycythemia vera, essential thrombocythemia, and primary myelofibrosis, enabling definitive diagnosis and disease monitoring. It is a molecular cornerstone that differentiates clonal myeloproliferative neoplasms from reactive conditions.
2. How accurate is this NGS method compared to older PCR tests?
With 99.9% diagnostic sensitivity and deep sequencing, our NGS platform reliably identifies mutations present in as few as 1% of blood cells, far surpassing standard allele‑specific PCR methods that can miss low‑level clones. This enables tracking of minimal residual disease for therapeutic decisions.
3. What are the pre‑test instructions for the JAK2 NGS blood draw?
You should undergo a genetic counseling session to review family history and draw a pedigree chart. For the blood draw itself, avoid aspirin, NSAIDs, or herbal supplements for 48 hours before collection. No fasting is required, but inform the phlebotomist about all current medications.
UAE Regulatory & Data Privacy Adherence
Your Data, Your Privacy, Our Commitment
DNA Labs UAE strictly complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genomic data is encrypted, access-controlled, and processed under lawful consent. Our DHA Facility License (No. 1143) ensures full regulatory oversight at our Dubai Healthcare City laboratory.
We do not share your genetic information with third parties without explicit written authorization. For more information, contact our Data Protection Officer.
Clinical & Logistical Metadata
| Test Name | JAK2 V617F Mutation Analysis (Somatic) by Next-Generation Sequencing (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 14–21 business days |
| Sample Type / Matrix | Whole blood (EDTA) or extracted DNA |
| Methodology Used | Next‑Generation Sequencing (NGS) with deep targeted sequencing and bioinformatics interpretation |
| ICD-10-CM Code | D45 (Polycythemia vera), D47.3 (Essential thrombocythemia), D47.1 (Primary myelofibrosis) |
| LOINC Code | 39380-3 (JAK2 mutation analysis) |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians